ResMed Story Overview

RMD -- USA Stock  

USD 105.80  0.30  0.28%

Macroaxis does not monitor all media channels or aggregates social signals for ResMed. But even though we do not provide professional-grade financial sentiment analysis on ResMed, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for ResMed. Additionally take a look at ResMed Hype Analysis, ResMed Correlation and ResMed Performance.
Exercise or conversion by Brett Sandercock of 5000 shares of ResMed subject to Rule 16b-3
Filed transaction by Resmed Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

ResMed Inc insider trading alert for exercise of resmed nq stock options by Brett Sandercock, Chief Financial Officer, on December 23, 2017. This event was filed by Resmed Inc with SEC on 2013-08-29. Statement of changes in beneficial ownership - SEC Form 4. Brett Sandercock is currently serves as cfo and principal accounting officer of ResMed Inc

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for ResMed

a day ago at www.macroaxis.com 
Sale by Rob Douglas of 500 shares of ResMed
Macroaxis News
Filed transaction by Resmed Inc officer. General open market or private sale of non-derivative or derivative security
few days ago at www.macroaxis.com 
Exercise or conversion by Smith Adrian M of 20000 shares of ResMed subject to Rule 16b-3
Macroaxis News
Filed transaction by Resmed Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at www.macroaxis.com 
Exercise or conversion by Peter Farrell of 27169 shares of ResMed subject to Rule 16b-3
Macroaxis News
Filed transaction by Resmed Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at http://www.nasdaq.com 
ResMed Reports Positive Results for Bilevel PAP Device Study
nasdaq News
NasdaqFull coverage
over two weeks ago at http://www.derbynewsjournal.com 
Sale by Hollingshead James of 600 shares of ResMed
wsj  News
Filed transaction by Resmed Inc officer. General open market or private sale of non-derivative or derivative security
over two weeks ago at http://stocknewsgazette.com 
Exercise or conversion by Rich Sulpizio of 28403 shares of ResMed subject to Rule 16b-3
news
Filed transaction by Resmed Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over two weeks ago at http://www.zacks.com 
Heres Why You Should Add ResMed to Your Portfolio Now
zacks News
Zacks.comFull coverage
over three weeks ago at http://danversrecord.com 
How is ResMed Inc Trending
news
Danvers RecordFull coverage
over three weeks ago at www.macroaxis.com 
Sale by Rob Douglas of 5000 shares of ResMed
Macroaxis News
Filed transaction by Resmed Inc officer. General open market or private sale of non-derivative or derivative security
over a month ago at www.macroaxis.com 
ResMed exotic insider transaction detected
Macroaxis News
Filed transaction by Resmed Inc officer. Unconventional Insider trading
over a month ago at www.macroaxis.com 
Payment of 5410 shares by Jacobsen Stein of ResMed subject to Rule 16b-3
Macroaxis News
Filed transaction by Resmed Inc officer. Payment of exercise price or tax liability by delivering or withholding securities
over two months ago at http://kldaily.com 
Citigroup Cuts ResMed Stock To a Neutral Rating
news
KL DailyCitigroup May Have Just Lost Faith in ResMed BZ WeeklyWhat Can We Expect After ResMed s Downgrade By Citigroup NMSU HeraldFull coverage
over three months ago at www.macroaxis.com 
Payment of 5425 shares by Rob Douglas of ResMed subject to Rule 16b-3
Macroaxis News
Filed transaction by Resmed Inc officer. Payment of exercise price or tax liability by delivering or withholding securities

Did you try this?

Run Aroon Oscillator Now
   

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
All  Next Launch Aroon Oscillator

Profit Margin

Profit Margin Comparative Analysis
  Profit Margin 
      ResMed Comparables 
ResMed is rated second in profit margin category among related companies. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Peers

ResMed Related Equities
BSX  3.26 %   
0%
100.0%
TFX  2.08 %   
0%
63.0%
HOLX  1.71 %   
0%
52.0%
COO  1.49 %   
0%
45.0%
VAR  0.89 %   
0%
27.0%
DGX  0.58 %   
0%
17.0%
XRAY  0.16 %   
4.0%
0%
RMD  0.28 %   
8.0%
0%
SYK  0.8 %   
24.0%
0%
DXCM  1.08 %   
33.0%
0%
Additionally take a look at ResMed Hype Analysis, ResMed Correlation and ResMed Performance. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.